From the Department of Medicine, University of Illinois Chicago, Chicago, IL.
Cancer J. 2023;29(2):61-69. doi: 10.1097/PPO.0000000000000644.
Lung cancer is the leading cause of cancer-related deaths. Over the past 10 years, significant advances in treatment modalities, including immune checkpoint inhibitor (ICI) blockade, have led to improved outcomes. Elucidating predicative biomarkers in responders and nonresponders to ICI will lead to development of therapeutic targets that could enhance ICI efficacy. Recently, the gut microbiome was identified as a predictive biomarker for ICI in patients with multiple cancer types. However, it is unclear how other host microbiomes influence tumorigenesis and response to ICI. Other groups have explored the lung microbiome as it relates to carcinogenesis and immunotherapy efficacy. In this review, we explore the role of the lung microbiome in health and disease. We also review the current state of lung microbiome research as it relates to tumorigenesis and treatments and provide potential insights into how the lung microbiome could improve outcomes in patients with cancer.
肺癌是癌症相关死亡的主要原因。在过去的 10 年中，治疗方式取得了重大进展，包括免疫检查点抑制剂（ICI）阻断，从而改善了治疗效果。阐明对 ICI 有反应者和无反应者的预测性生物标志物将有助于开发可增强 ICI 疗效的治疗靶点。最近，肠道微生物组被确定为多种癌症类型患者接受 ICI 的预测性生物标志物。然而，其他宿主微生物组如何影响肿瘤发生和对 ICI 的反应尚不清楚。其他研究小组已经研究了与致癌作用和免疫治疗疗效相关的肺部微生物组。在这篇综述中，我们探讨了肺部微生物组在健康和疾病中的作用。我们还回顾了肺部微生物组研究的现状，以及与肿瘤发生和治疗的关系，并提供了有关肺部微生物组如何改善癌症患者预后的潜在见解。
